Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MNOVthis companyMediciNova, Inc.	$1.44	-5.46×	1.55×	156.89×	-2.81×	-57.3%	7.6%	-3242.5%	-2928.8%	-28.9%	-31.6%	-15.3%	0×	2.56×	0×	8.16×	0.0%	2	-2.11	3	B-
ACRVAcrivon Therapeutics, Inc. Common Stock	$1.67	-1.19×	0.82×	0×	-0.71×	-40.7%	0.0%	0.0%	0.0%	-69.2%	-73.0%	-70.4%	0.02×	0.51×	0×	7.69×	0.0%	1	-2.78	3	B-
BMEABiomea Fusion, Inc.	$0.60	-1.05×	2.19×	0×	-0.17×	48.4%	0.0%	0.0%	0.0%	-209.1%	-166.2%	-108.7%	0.05×	0.9×	0×	5.23×	0.0%	0	-18.95	2	C+
CBUSCibus, Inc.	$1.21	-0.63×	3.65×	21.88×	-3.72×	-625.8%	-62.8%	-1853.9%	-3492.3%	-582.2%	-23.2%	-64.3%	12.28×	-2.84×	-1.9×	0.72×	0.0%	3	-4.45	1	D+
FBIOFortress Biotech, Inc.	$1.97	-54.3×	2.05×	1.61×	-4.81×	-588.7%	66.9%	-111.0%	10.8%	13.7%	-50.0%	-64.4%	1.49×	0.25×	-8.06×	2.49×	0.7%	6	0.11	4	A
IMUXImmunic, Inc.	$7.99	-0.86×	-12.46×	0×	-0.7×	-91.8%	0.0%	0.0%	0.0%	1456.2%	1693.4%	-103.4%	-0.1×	0.15×	0×	0.75×	0.0%	2	-5.39	2	C
Peer median	—	-1.05×	2.05×	0×	-0.71×	-91.8%	0.0%	0.0%	0.0%	-69.2%	-50.0%	-70.4%	0.05×	0.25×	0×	2.49×	0.0%	2	-4.45	2	—